ReP USP - Resultado da busca

Artigo de periodico
Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach (2020)
Coelho, Eduardo Barbosa ; Cusinato, Diego Alberto Ciscato ; Ximenez, João Paulo Bianchi ; Lanchote, Vera Lucia ; Struchiner, Claudio José; Suarez-Kurtz, Guilherme
Source: Frontiers in Pharmacology. Unidades: FMRP, FCFRP
Subjects: CAFEÍNA, ANTI-HISTAMÍNICOS, FÁRMACOS (SISTEMA DIGESTÓRIO), FENÓTIPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COELHO, Eduardo Barbosa et al. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach. Frontiers in Pharmacology, v. 11, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.3389/fphar.2020.00022. Acesso em: 16 nov. 2024.
APA
Coelho, E. B., Cusinato, D. A. C., Ximenez, J. P. B., Lanchote, V. L., Struchiner, C. J., & Suarez-Kurtz, G. (2020). Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach. Frontiers in Pharmacology, 11, 1-7. doi:10.3389/fphar.2020.00022
NLM
Coelho EB, Cusinato DAC, Ximenez JPB, Lanchote VL, Struchiner CJ, Suarez-Kurtz G. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach [Internet]. Frontiers in Pharmacology. 2020 ; 11 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fphar.2020.00022
Vancouver
Coelho EB, Cusinato DAC, Ximenez JPB, Lanchote VL, Struchiner CJ, Suarez-Kurtz G. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach [Internet]. Frontiers in Pharmacology. 2020 ; 11 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fphar.2020.00022
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 16 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Subjects: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 16 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113231. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Artigo de periodico
Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease (2020)
Schaab, Estela Hanauer; Lanchote, Vera Lucia ; Nardotto, Glauco Henrique Balthazar ; Pereira, Maria Paula Marques ; Dantas, Márcio ; Paiva, Carlos Eduardo; Coelho, Eduardo Barbosa
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: NEFROPATIAS, INTERAÇÃO ENTRE ALIMENTOS E MEDICAMENTOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHAAB, Estela Hanauer et al. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, v. 60, n. 1, p. 75-85, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1485. Acesso em: 16 nov. 2024.
APA
Schaab, E. H., Lanchote, V. L., Nardotto, G. H. B., Pereira, M. P. M., Dantas, M., Paiva, C. E., & Coelho, E. B. (2020). Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, 60( 1), 75-85. doi:10.1002/jcph.1485
NLM
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1485
Vancouver
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1485
Artigo de periodico
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia (2020)
Oliveira, Milena Locci de ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Pippa, Leandro Francisco ; Simões, Belinda Pinto ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, METABÓLITOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Milena Locci de et al. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, v. 191, p. 1-8, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113576. Acesso em: 16 nov. 2024.
APA
Oliveira, M. L. de, Rocha, A., Nardotto, G. H. B., Pippa, L. F., Simões, B. P., & Lanchote, V. L. (2020). Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, 191, 1-8. doi:10.1016/j.jpba.2020.113576
NLM
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Vancouver
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Artigo de periodico
Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe (2020)
Caris, Juciene Aparecida ; Benzi, Jhohann Richard de Lima ; Souza, Flávio Falcão Lima de; Oliveira, Renê Donizeti Ribeiro de; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia
Source: European Journal of Pharmaceutical Sciences. Unidades: FMRP, FCFRP
Subjects: ARTRITE REUMATOIDE, METABOLISMO, ESTUDOS DE CASOS E CONTROLES, CITOCROMO P-450, ESTATINAS, NECROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARIS, Juciene Aparecida et al. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. European Journal of Pharmaceutical Sciences, v. 146, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2020.105264. Acesso em: 16 nov. 2024.
APA
Caris, J. A., Benzi, J. R. de L., Souza, F. F. L. de, Oliveira, R. D. R. de, Donadi, E. A., & Lanchote, V. L. (2020). Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. European Journal of Pharmaceutical Sciences, 146, 1-7. doi:10.1016/j.ejps.2020.105264
NLM
Caris JA, Benzi JR de L, Souza FFL de, Oliveira RDR de, Donadi EA, Lanchote VL. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe [Internet]. European Journal of Pharmaceutical Sciences. 2020 ; 146 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejps.2020.105264
Vancouver
Caris JA, Benzi JR de L, Souza FFL de, Oliveira RDR de, Donadi EA, Lanchote VL. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe [Internet]. European Journal of Pharmaceutical Sciences. 2020 ; 146 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejps.2020.105264
Artigo de periodico
A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women (2020)
Benzi, Jhohann Richard de Lima ; Moreira, Fernanda de Lima; Marques, Maria Paula ; Duarte, Geraldo; Suarez-Kurtz, Guilherme; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP
Subjects: LÍQUIDOS CORPORAIS, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CITOCROMO P-450, INFECÇÕES POR HIV, CORTISOL, ESPECTROMETRIA DE MASSAS, FENÓTIPOS, GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENZI, Jhohann Richard de Lima et al. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, v. 1144 , 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122074. Acesso em: 16 nov. 2024.
APA
Benzi, J. R. de L., Moreira, F. de L., Marques, M. P., Duarte, G., Suarez-Kurtz, G., & Lanchote, V. L. (2020). A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, 1144 . doi:10.1016/j.jchromb.2020.122074
NLM
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Vancouver
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Artigo de periodico
Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers (2020)
Cestari, Roberta Natália ; Caris, Juciene Aparecida ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Oliveira, Renê Donizeti Ribeiro de; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ESTATINAS, FARMACOCINÉTICA, FARMACOLOGIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, COMPOSTOS ORGÂNICOS, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, v. 182, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113128. Acesso em: 16 nov. 2024.
APA
Cestari, R. N., Caris, J. A., Rocha, A., Nardotto, G. H. B., Oliveira, R. D. R. de, & Lanchote, V. L. (2020). Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 182, 1-7. doi:10.1016/j.jpba.2020.113128
NLM
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Vancouver
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Artigo de periodico
Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients (2020)
Ximenez, João Paulo Bianchi ; Lanchote, Vera Lucia ; Bello, Marcelo A.; Iocken, Fernanda H. S.; Obadia, Renata C. M.; Sousa, Valéria Pereira de; Suarez-Kurtz, Guilherme
Source: Basic Clinical Pharmacology & Toxicology. Unidades: FCFRP, FMRP
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA, RECEPTORES DE DROGA, ESTRÓGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIMENEZ, João Paulo Bianchi et al. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients. Basic Clinical Pharmacology & Toxicology, v. 126, n. 5, p. 432-436, 2020Tradução . . Disponível em: https://doi.org/10.1111/bcpt.13368. Acesso em: 16 nov. 2024.
APA
Ximenez, J. P. B., Lanchote, V. L., Bello, M. A., Iocken, F. H. S., Obadia, R. C. M., Sousa, V. P. de, & Suarez-Kurtz, G. (2020). Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients. Basic Clinical Pharmacology & Toxicology, 126( 5), 432-436. doi:10.1111/bcpt.13368
NLM
Ximenez JPB, Lanchote VL, Bello MA, Iocken FHS, Obadia RCM, Sousa VP de, Suarez-Kurtz G. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients [Internet]. Basic Clinical Pharmacology & Toxicology. 2020 ; 126( 5): 432-436.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcpt.13368
Vancouver
Ximenez JPB, Lanchote VL, Bello MA, Iocken FHS, Obadia RCM, Sousa VP de, Suarez-Kurtz G. Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients [Internet]. Basic Clinical Pharmacology & Toxicology. 2020 ; 126( 5): 432-436.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcpt.13368
Artigo de periodico-carta/editorial
Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] (2020)
Vieira, Carolina Pinto; Neves, Daniel Valente; Nardotto, Glauco Henrique Balthazar; Cesarino, Evandro José ; Rocha, Adriana; Zanardi, Ailton Marcelo Castilho Teno; Lanchote, Vera Lucia
Source: European Journal of Clinical Pharmacology. Unidade: FCFRP
Subjects: BETA-BLOQUEADORES, HIPERTENSÃO, METABOLISMO, IDOSOS, FARMACOCINÉTICA, DOENÇA DE CHAGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEIRA, Carolina Pinto et al. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s00228-020-02837-9. Acesso em: 16 nov. 2024. , 2020
APA
Vieira, C. P., Neves, D. V., Nardotto, G. H. B., Cesarino, E. J., Rocha, A., Zanardi, A. M. C. T., & Lanchote, V. L. (2020). Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1007/s00228-020-02837-9
NLM
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Vancouver
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Artigo de periodico
Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics (2020)
Pinto, Leonardo Santos Ribeiro; Moreira, Fernanda de Lima ; Nardotto, Glauco Henrique Balthazar ; Cavalli, Ricardo de Carvalho ; Moisés, Elaine Christine Dantas ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTIDEPRESSIVOS, FARMACOCINÉTICA, GRAVIDEZ, ESTUDOS DE CASOS E CONTROLES, MUCOSA INTESTINAL, ANTI-HISTAMÍNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, v. 37, n. 7, 2020Tradução . . Disponível em: https://doi.org/10.1007/s11095-020-02854-4. Acesso em: 16 nov. 2024.
APA
Pinto, L. S. R., Moreira, F. de L., Nardotto, G. H. B., Cavalli, R. de C., Moisés, E. C. D., Duarte, G., & Lanchote, V. L. (2020). Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, 37( 7). doi:10.1007/s11095-020-02854-4
NLM
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Vancouver
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Artigo de periodico
A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: LÍQUIDO AMNIÓTICO, FÁRMACOS DIURÉTICOS, GRAVIDEZ, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ, CESÁREA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section. The Journal of Clinical Pharmacology, v. 60, n. 12, p. 1655-1661, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1681. Acesso em: 16 nov. 2024.
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Duarte, G., & Lanchote, V. L. (2020). A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section. The Journal of Clinical Pharmacology, 60( 12), 1655-1661. doi:10.1002/jcph.1681
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Duarte G, Lanchote VL. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 12): 1655-1661.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1681
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Duarte G, Lanchote VL. A pilot study of the maternal-fetal pharmacokinetics of furosemide in plasma, urine, and amniotic fluid of hypertensive parturient women under cesarean section [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 12): 1655-1661.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1681
Artigo de periodico
Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin (2020)
Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro de; Souza, Flávio Falcão Lima de; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: LÚPUS ERITEMATOSO SISTÊMICO, FARMACOCINÉTICA, FÁRMACOS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, v. 13, n. 6, p. 1227-1235, 2020Tradução . . Disponível em: https://doi.org/10.1111/cts.12808. Acesso em: 16 nov. 2024.
APA
Cestari, R. N., Oliveira, R. D. R. de, Souza, F. F. L. de, Pippa, L. F., Nardotto, G. H. B., Rocha, A., et al. (2020). Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, 13( 6), 1227-1235. doi:10.1111/cts.12808
NLM
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.12808
Vancouver
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.12808
Artigo de periodico
Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics (2020)
Godoy, Ana Leonor Pardo Campos; Jesus, Clauceane de; Gonçalves, Rafaela S.; Azeredo, Francine Johansson; Rocha, Adriana; Marques, Maria Paula ; Lanchote, Vera Lucia ; Larangeira, Daniela Farias; Barrouin-Melo, Stella Maria
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidade: FCFRP
Subjects: ÁCIDO ÚRICO, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CÃES, URINA, PARASITOLOGIA, LEISHMANIA INFANTUM, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GODOY, Ana Leonor Pardo Campos et al. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113204. Acesso em: 16 nov. 2024.
APA
Godoy, A. L. P. C., Jesus, C. de, Gonçalves, R. S., Azeredo, F. J., Rocha, A., Marques, M. P., et al. (2020). Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113204
NLM
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204
Vancouver
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204
Artigo de periodico
Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study (2020)
Moreira, Fernanda de Lima ; Marques, Maria Paula ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FMRP, FCFRP
Subjects: FÁRMACOS, ANTIRRETROVIRAIS, GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOREIRA, Fernanda de Lima et al. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, v. 177, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2019.112838. Acesso em: 16 nov. 2024.
APA
Moreira, F. de L., Marques, M. P., Duarte, G., & Lanchote, V. L. (2020). Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 177. doi:10.1016/j.jpba.2019.112838
NLM
Moreira F de L, Marques MP, Duarte G, Lanchote VL. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 177[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2019.112838
Vancouver
Moreira F de L, Marques MP, Duarte G, Lanchote VL. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 177[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2019.112838
Artigo de periodico
Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy (2020)
Souza, Marília Cristina Oliveira ; Pereira, Maria Paula Marques ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: ANESTÉSICOS, PARTO, FARMACOCINÉTICA, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Marília Cristina Oliveira et al. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy. The Journal of Clinical Pharmacology, v. 60, n. 5, p. 566-572, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1554. Acesso em: 16 nov. 2024.
APA
Souza, M. C. O., Pereira, M. P. M., Duarte, G., & Lanchote, V. L. (2020). Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy. The Journal of Clinical Pharmacology, 60( 5), 566-572. doi:10.1002/jcph.1554
NLM
Souza MCO, Pereira MPM, Duarte G, Lanchote VL. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 5): 566-572.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1554
Vancouver
Souza MCO, Pereira MPM, Duarte G, Lanchote VL. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 5): 566-572.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1554

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies

Indexado em

Non normalized affiliation